Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31. Mai 2022 18:15 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2022 that...
Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
04. Mai 2022 16:05 ET
|
Sarepta Therapeutics, Inc.
Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for the first quarter 2022 totaled $188.8...
Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
04. Mai 2022 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29. April 2022 18:23 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 29, 2022...
Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022
27. April 2022 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31. März 2022 18:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2022...
Sarepta Therapeutics anuncia quinto año de Route 79, El Programa de Becas Duchenne
08. März 2022 08:30 ET
|
Sarepta Therapeutics, Inc.
El sitio web de solicitud ya está abierto para el Programa de Becas 2022Para el año académico 2022-2023, el programa de becas fue expandido para incluir dos grupos: uno para personas que viven con...
Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program
08. März 2022 08:30 ET
|
Sarepta Therapeutics, Inc.
Application website is now open for the 2022 Scholarship ProgramFor the 2022-2023 academic year, the scholarship program has expanded to include two groups: one for individuals living with Duchenne...
Sarepta Therapeutics to Present at Upcoming Investor Conferences
02. März 2022 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
01. März 2022 16:05 ET
|
Sarepta Therapeutics, Inc.
Total revenues, which consist primarily of net product revenues and collaboration revenues, for the fourth quarter and full-year 2021 totaled $201.5 million and $701.9 million, respectivelyNet product...